pharma · Prurigo Nodularis · Vitiligo
Incyte
Incyte clinical programs — 29 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1801 Augustine Cut-Off, Wilmington, Delaware 19803, US
- Employees
- 3,381
- Programs
- 53
- Drugs
- 61
- Patents
- 0
Incyte projects
29 ClinicalTrials.gov programs sponsored by Incyte.
Incyte has 29 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Axatilimab (INCA034176)
Incyte
Chronic Graft-Versus-Host Disease
1 trial -
INCA033890-303
Incyte
Metastatic Microsatellite Stable Colorectal Cancer
1 trial -
INCA34176-357
Incyte
chronic graft-versus-host disease
1 trial -
INCB 18424-309
Incyte
Vitiligo
1 trial -
INCB 18424-326
Incyte
Atopic Dermatitis
1 trial -
INCB 54707-305
Incyte
Prurigo Nodularis
1 trial -
INCB 54707-306
Incyte
Prurigo Nodularis
1 trial -
INCB 54828-302
Incyte
Cholangiocarcinoma
1 trial -
INCB018424-316
Incyte
Atopic Dermatitis
1 trial -
INCB018424-324
Incyte
Hidradenitis Suppurativa
1 trial -
INCB018424-325
Incyte
Hidradenitis Suppurativa
1 trial -
INCB054707-801
Incyte
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
1 trial -
INCB123667-305
Incyte
Ovarian cancer
1 trial -
INCB18424-320
Incyte
Prurigo Nodularis
1 trial -
INCMGA 0012-304
Incyte
Metastatic nonsquamous or squamous non-small cell lung cancer
1 trial -
INCMOR 0208-305
Incyte
Diffuse large B-cell lymphoma (DLBCL)
1 trial -
INCMOR0208-301
Incyte
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
1 trial -
MINJUVI 200 mg powder for concentrate for solution for infusion
Incyte
Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia
1 trial -
MK-3475-669
Incyte
Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies
1 trial -
MK-3475-679
Incyte
Locally advanced/metastatic renal cell carcinoma
1 trial -
MOR208C310
Incyte
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)
1 trial -
Pembrolizumab
Incyte
Renal Cell Carcinoma (RCC)
1 trial -
Pemigatinib
Incyte
Unresectable Cholangiocarcinoma
1 trial -
Placebo to Povorcitinib, Povorcitinib
Incyte
Vitiligo
1 trial -
Povorcitinib
Incyte
Hidradenitis Suppurativa (HS)
1 trial -
Povorcitinib, Placebo to Povorcitinib
Incyte
Vitiligo
1 trial -
Povorcitinib, Povorcitinib
Incyte
Hidradenitis Suppurativa
1 trial -
Retifanlimab (INCMGA00012) for Squamous Carcinoma of the Anal Canal
Incyte
Squamous Carcinoma of the Anal Canal
1 trial -
Rituximab (RTX)
Incyte
Diffuse Large B-cell Lymphoma
1 trial
Frequently asked questions
How many clinical projects does Incyte have?
29 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.